SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nymox Pharmaceutical Corp – ‘6-K’ for 6/30/16

On:  Monday, 8/22/16, at 9:37am ET   ·   For:  6/30/16   ·   Accession #:  1176256-16-641   ·   File #:  1-12033

Previous ‘6-K’:  ‘6-K’ on 5/16/16 for 3/31/16   ·   Next:  ‘6-K’ on 11/15/16 for 9/30/16   ·   Latest:  ‘6-K’ on / for 3/28/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/22/16  Nymox Pharmaceutical Corp         6-K         6/30/16    4:298K                                   e3 Fil… Computershare/FA

Report by a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of Foreign Issuer for the Period Ended June  HTML      9K 
                          30, 2016                                               
 2: EX-99.1     Quarterly Report for the Quarter Ended June 30,     HTML    194K 
                          2016                                                   
 3: EX-99.2     CEO Certifications                                  HTML     12K 
 4: EX-99.3     CFO Certifications                                  HTML     12K 


6-K   —   Report of Foreign Issuer for the Period Ended June 30, 2016


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K  



FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the period ended June 30, 2016

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F [ X ] Form 40-F [   ]

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): [   ]

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [   ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [   ] No [ X ]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______________





Exhibits  
   
99.1 Quarterly Report for the Quarter ended June 30, 2016
99.2 CEO Certifications
99.3 CFO Certifications





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION

(Registrant)

 

 

By: /s/ Paul Averback, MD
Paul Averback, MD
President and Chief Executive Officer

 

 

Date: August 19, 2016




Dates Referenced Herein

This ‘6-K’ Filing    Date    Other Filings
Filed on:8/22/16None on these Dates
8/19/16
For Period End:6/30/16
 List all Filings 
Top
Filing Submission 0001176256-16-000641   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 19, 3:58:06.1am ET